Shahin Gharakhanian MD Consulting LLC, 2022 Mid-Year Report:

July 20, 2022

Selected Projects listed in alphabetical order:

[ACTICOR-BIOTECH, Paris, France]

• US Medical Executive for Acticor Biotech
• Developing Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.
• ACTISAVE phase II/III Study [(NCT05070260] ongoing.
• Please refer to : www.acticor-biotech.com

[DECOY Therapeutics, Cambridge MA, USA]

• Chair SAB: Scientific Advisory Board
• Developing a <Broad based Antiviral Platform>.
• Please refer to:
• decoytx.com
• jnjinnovation.com › JLABSNavigator › company

[DEINOVE, Montpellier, France]

• Executive Medical Consultant.
• Phase II: Canada-US clinical  trial assessing DNV3837: a novel GI tract-targeted parenteral treatment for Clostridioides difficile infections.
• Please refer to : www.deinove.com

[ENTERA HEALTH, Ankeny, IA, USA]

• Scientific Advisor.
• Clinical Trial for mild to moderate Covid-19 Infection.